Bristol Myers Squibb to build $2.3 billion Houston campus

Bristol Myers Squibb to build $2.3 billion Houston campus

Mon, August 10, 2026 at 8:37 PM GMT+3 2 min read

• BMY +0.46%

Bristol Myers Squibb announced Monday it will build a $2.3 billion drug manufacturing campus in Houston, Texas, part of the company's broader $40 billion commitment to invest in the United States over five years.

The roughly 600,000-square-foot campus will be located at Generation Park, a 4,300-acre site in Houston. The facility is designed to manufacture multiple types of medicines, including small molecules, biologics, and antibody-drug conjugates, the company said. The campus is engineered so that its production footprint can grow or shift in response to the company's evolving drug pipeline.

Bristol Myers expects the campus to employ nearly 500 people in roles spanning operations, production, engineering, quality control, and administration. Bristol Myers also estimates that construction activity at the site will support roughly 2,000 workers through 2030 before operations fully launch.

"This investment reflects our confidence in America's continued leadership in biopharmaceutical innovation," Bristol Myers Squibb Board Chair and Chief Executive Officer Christopher Boerner said in a statement. "Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life."

Texas Governor Greg Abbott announced that Bristol Myers is eligible for a $4.89 million grant through the Texas Enterprise Fund, and that the project also meets the criteria for incentives under the state's Jobs, Energy, Technology and Innovation program, according to Reuters.

The company said it selected Generation Park after evaluating multiple markets in the central and eastern United States, with key factors including workforce availability in life sciences, incentives, and proximity to utilities and transportation infrastructure.

Bristol Myers raised its full-year revenue forecast earlier this year, with second-quarter results fueled by the blood thinner Eliquis alongside newer drugs including heart treatment Camzyos and anemia drug Reblozyl. The company lifted its full-year revenue guidance to approximately $49 billion to $50 billion.

The Houston announcement comes as major drugmakers have been expanding their U.S. manufacturing commitments. Among those committing capital to domestic production are Eli Lilly, Johnson & Johnson, Roche, and Pfizer, all of which have unveiled significant U.S. investment plans, according to Reuters. Bristol Myers invested approximately $10 billion in research and development in 2025, the company said.